Below are all of the latest news articles relating to
CXR Biosciences. Click on a news headline to read the full article:
| Serologicals Corporation Announces Collaboration with CXR Biosciences To Establish New Drug Screening Platform
Sunday 1.1.06
Serologicals Corporation Announces Collaboration with CXR Biosciences To Establish New Drug Screening Platform
High Throughput In Vitro Multiple Readout Screens Expected to Reduce Development Time of New Therapies
|
| CXR is granted a UK patent for the Hepatic Reductase Null (HRN) model and launches the immunocompromised “nude” HRN mouse.
Friday 30.12.05
CXR Biosciences Ltd, the Dundee based drug development solutions company and innovator of new drug discovery and development technologies, today announced that the UK patent office has granted a patent covering the HRN mouse. This model greatly facilitates the assessment of the role of metabolism in determining the efficacy, bioavailability, and toxicity of drug candidates...
|
| CXR Biosciences Ltd Launches Investigative Toxicology Service Using Agilent Microarray Technology for Transcriptional Profiling.
Wednesday 1.9.04
CXR Biosciences has expanded its repertoire of drug discovery services by launching an Investigative Toxicology service using Transcriptional Profiling. This technology measures changes in gene expression following exposure to compounds and enhances the ability to determine if toxicity data from preclinical studies is relevant to man. If the reported toxicity can be demonstrated...
|
| CXR Biosciences Ltd. announces research collaboration with CopyRat Pty. Ltd.
Monday 12.7.04
CXR Biosciences Ltd., the innovator in new preclinical drug development technologies based in Dundee, UK, today announced that it has signed a collaborative agreement with CopyRat Pty. Ltd of Melbourne Australia. Under the terms of the agreement CXR Biosciences will work with CopyRat...
|
| CXR announces partnership with Geron & Roslin Institute
Thursday 20.5.04
CXR Biosciences Ltd. (Dundee, Scotland), Geron Corporation (Nasdaq: GERN), and the Roslin Institute (Edinburgh, Scotland) today announced a collaboration to develop and commercialize human embryonic stem cell (hESC)-derived hepatocytes for use in in vitro assays of drug metabolism and toxicity...
|
| CXR Biosciences announce research agreement with the ECPI
Tuesday 13.1.04
CXR Biosciences Ltd., the innovator in new preclinical drug development technologies based in Dundee, UK, today announced that it has signed a research agreement with the European Council for Plasticisers and Intermediates (ECPI). Under the terms of the agreement...
|
| CXR Biosciences announce research agreement with Procter and Gamble
Tuesday 2.12.03
CXR Biosciences Ltd., the innovator in new preclinical drug development technologies based in Dundee,UK,today announced that it has signed a research agreement with P & G. Under the terms of the agreement CXR Biosciences will develop customised in vitro assays...
|
| CXR Biosciences Ltd. Raises Additional Capital
Monday 25.8.03
CXR Biosciences Ltd., the innovator in new preclinical drug development technologies based in Dundee,UK, announced today the investment in the Company of £440,000 by the Archangel investment group. ..
|
| CXR Biosciences and Roslin Institute signs collaboration agreement with Schering-Plough
Friday 1.11.02
CXR Biosciences, the Dundee-based drug development technology company today announced that it has signed a research agreement with Schering-Plough Research Institute, the research and development arm of Schering-Plough Corporation, based in...
|
| CXR Biosciences appoints new Chief Executive
Monday 1.7.02
CXR Biosciences Ltd., a major new pre-clinical drug development and drug discovery company formed at the beginning of the year as a £4 million...
|
CXR Biosciences is a partner in a ten million Euro R&D ..
